Federated Hermes Inc. Sells 64,794 Shares of Danaher Corporation $DHR

Federated Hermes Inc. cut its holdings in shares of Danaher Corporation (NYSE:DHR) by 31.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 143,628 shares of the conglomerate’s stock after selling 64,794 shares during the quarter. Federated Hermes Inc.’s holdings in Danaher were worth $28,372,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Ceredex Value Advisors LLC grew its stake in Danaher by 1.6% during the second quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock worth $49,262,000 after buying an additional 3,862 shares in the last quarter. Chicago Capital LLC boosted its position in shares of Danaher by 11.6% during the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after acquiring an additional 1,391 shares in the last quarter. Weitz Investment Management Inc. increased its stake in Danaher by 6.1% in the second quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock valued at $104,094,000 after acquiring an additional 30,300 shares during the last quarter. UniSuper Management Pty Ltd raised its position in Danaher by 1.6% during the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after purchasing an additional 2,667 shares in the last quarter. Finally, Nvwm LLC raised its position in Danaher by 20.4% during the second quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock valued at $1,401,000 after purchasing an additional 1,204 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DHR has been the topic of several recent analyst reports. Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Redburn Partners set a $220.00 target price on Danaher in a research note on Wednesday, October 8th. Morgan Stanley initiated coverage on shares of Danaher in a report on Monday, December 1st. They issued an “overweight” rating and a $270.00 target price for the company. Bank of America decreased their price target on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Finally, Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research note on Tuesday, September 2nd. Twenty-one investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $246.79.

Danaher Stock Down 0.4%

Shares of DHR opened at $223.51 on Wednesday. The stock’s 50-day moving average price is $217.50 and its two-hundred day moving average price is $205.01. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $258.23. The company has a market capitalization of $157.87 billion, a PE ratio of 46.08, a PEG ratio of 4.36 and a beta of 0.89. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the firm earned $1.71 earnings per share. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. On average, analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s dividend payout ratio is currently 26.39%.

Insider Transactions at Danaher

In related news, Director Teri List sold 3,298 shares of Danaher stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the transaction, the director owned 20,762 shares of the company’s stock, valued at $4,702,593. This trade represents a 13.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 30,248 shares of company stock worth $6,609,663 over the last three months. 11.20% of the stock is owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.